| Aim To ascertain whether the low density lipoprotein receptor-related protein 8(LRP8) and the neuropeptide Y receptor 2 (NPY2r) polymorphisms are associated with the afficacy of treatment of essential hypertensive patients with Benazepril. Methods We conducted essential hypertensive subjects from two Counties of Anhui, China, respectively. Both systolic and diastolic blood pressures (SBP and DBP) before and after 15-day benazepril treatment were measured. LRP8 genotypes were determined for all subjects. We selected 422 objects of SBP or DBP decrease and increase extremely value to detemined the LRP8 and NPY2R genotype and analyse the association between the gene polymorphism and afficacy of the Benazepril treatment. Results 1. LPR8 Polymorphism and Systolic and Diastolic Blood Pressure Decreases After 15 days of Benazepril Treatment. (1 )The age, weight, the body mass index, the baseline of systolic blood pressure and the diastolic blood pressure are not differ with two subpopulation. (2) The frequency of LRP8 genotypes are equal and no significant different with Hard-weiberg equivalent tests. (3) The LRP8 polymorphism was associated with SBP decrease in response to the 15-day benazepril treatment in subpopulation with BMK24kg/m2 (Crude: β±S: 5.00±2.63mmHg, P = 0.0573;Adjusted: β±SE: 5.18±2.52mmHg), p=0.0395).However, there was no associated with SBP decrease and DBP decrease in response to 15-day benazepril treatment in subpopulation with BMI>=24kg/m2. And we also found that the LRP8 polymorphism was associated with SBP and DBP decrease in response to the 15-day benazepril treatment in subpopulation with mild BP subpopulation (159=>SBP>=140mmHg or 99=>DBP>=90mmHg) (SBP decrease, Crude: p±SE:5.99±2.49mmHg, p=0.0162; Adjusted: β±SE: 5.98±2.41mmHg , p=0.0162; DBP decrease, Crude:... |
PDF Full Text Request